Vistusertib,AZD4547,Capivasertib,Sapitinib,Selumetinib,Vandetanib,durvalumab,savolitinib,Olaparib
astrazeneca,sanofi,hutchmed,merck,otsuka
['sclc', 'nsclc', 'lung', 'durva']
#asco23 unicancer safir02-lung explores ctdna in nsclc pts on durvalumab maintenance post-chemo 16% pts tumor fraction (tf) 2% lower pfs (1.7m vs 5.8m) &amp; os (10.4m vs 25.9m) in tf 2% pts
? limited benefit of durvalumab for tf+ pts 
Fellow @MayoHemeOnc | @UConnIM| @UTexasSPH| @MDAndersonNews|@COVID19nCCC| #SoMeEditor @JCOCCI_ASCO| Co-Host @HemOncFellows @LungCancerRX https://t.co/dsiuV460lQ